Evidence map›Paper›PMID 38569493›Full record

ReviewBiofabrication2024

3D printing processes in precise drug delivery for personalized medicine.

Haisheng Peng, Bo Han, Tianjian Tong, Xin Jin, Yanbo Peng, Meitong Guo, Bian Li, Jiaxin Ding, Qingfei Kong, Qun Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biofabrication, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Haisheng PengDepartment of Pharmacology, Medical College, University of Shaoxing, Shaoxing, People's Republic of China.
Bo HanDepartment of Pharmacy, Daqing Branch, Harbin Medical University, Daqing, People's Republic of China.
Tianjian TongDepartment of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, United States of America.
Xin JinDepartment of Pharmacology, Medical College, University of Shaoxing, Shaoxing, People's Republic of China.
Yanbo PengDepartment of Pharmaceutical Engineering, China Pharmaceutical University, 639 Longmian Rd, Nanjing 211198, People's Republic of China.
Meitong GuoDepartment of Pharmacology, Medical College, University of Shaoxing, Shaoxing, People's Republic of China.
Bian LiDepartment of Pharmacology, Medical College, University of Shaoxing, Shaoxing, People's Republic of China.
Jiaxin DingDepartment of Pharmacology, Medical College, University of Shaoxing, Shaoxing, People's Republic of China.
Qingfei KongDepartment of Neurobiology, Harbin Medical University, Heilongjiang Provincial Key Laboratory of Neurobiology, Harbin, Heilongjiang 150086, People's Republic of China.
Qun WangDepartment of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, United States of America.ORCID 0000-0002-5660-5602

Funding

Rational Design of Oral Drugs Targeting Mucosa DeliveryR21EB032991 · NIBIB · IOWA STATE UNIVERSITY · PI WANG, QUN · 2022 to 2024
$612k
NIBIB NIH HHS R21 EB032991
6 · The paper itself

Abstract

With the advent of personalized medicine, the drug delivery system will be changed significantly. The development of personalized medicine needs the support of many technologies, among which three-dimensional printing (3DP) technology is a novel formulation-preparing process that creates 3D objects by depositing printing materials layer-by-layer based on the computer-aided design method. Compared with traditional pharmaceutical processes, 3DP produces complex drug combinations, personalized dosage, and flexible shape and structure of dosage forms (DFs) on demand. In the future, personalized 3DP drugs may supplement and even replace their traditional counterpart. We systematically introduce the applications of 3DP technologies in the pharmaceutical industry and summarize the virtues and shortcomings of each technique. The release behaviors and control mechanisms of the pharmaceutical DFs with desired structures are also analyzed. Finally, the benefits, challenges, and prospects of 3DP technology to the pharmaceutical industry are discussed.

Indexed as

Drug Delivery SystemsPrecision MedicineComputer-Aided DesignPharmaceutical PreparationsPrinting, Three-DimensionalPharmaceutical Preparations3D printingdosage formpersonalized medicineprecise drug delivery

Identifiers

PMID38569493
PMCPMC11164598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.